ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

8,887 trials analyzed so far

Trials that use: Cox proportional-hazards model

New to this method? Read the tutorial →

399 results

RECESSComplete statistical analysis of the RECESS phase 3 trial comparing shorter- and longer-storage red blood cell units in patients undergoing cardiac surgery, including MODS, mortality, complications, and statistical methodology.Phase 3Results postedn = 1,481NCT00991341
RECIAIndependent statistical analysis of Multifactorial Approach to Emergent Cerclage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01114516).Phase NAResults postedn = 53NCT01114516
RECORD-4Independent statistical analysis of Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01491672).Phase 2Results postedn = 134NCT01491672
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 48NCT02289209
RELEASEIndependent statistical analysis of PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 41NCT04099888
RESPIRE 1Independent statistical analysis of Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 416NCT01764841
RIVER-PCIComplete statistical analysis of RIVER-PCI, a randomized phase 3 trial of ranolazine versus placebo after PCI in patients with coronary artery disease and angina pectoris, including time-to-event endpoints, Cox modeling, hazard ratios,…Phase 3Results postedn = 2,651NCT01442038
ROCKETIndependent statistical analysis of A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 62NCT02096354
ROCKET AFIndependent statistical analysis of ROCKET AF, the randomized phase 3 trial of rivaroxaban versus warfarin for prevention of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation.Phase 3Results postedn = 14,269NCT00403767
RSVHRIndependent statistical analysis of A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 187NCT05568706
RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…Phase 3Results postedn = 544NCT00533949
RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.Phase 3Results postedn = 5,018NCT01272037
S1216A detailed statistical analysis of S1216, a randomized phase 3 trial comparing LHRHa plus TAK-700 with LHRHa plus bicalutamide in metastatic prostate cancer, including overall survival, progression-free survival, Cox modeling, hazard ratios,…Phase 3Results postedn = 1,313NCT01809691
SANDPIPERIndependent statistical analysis of A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase…Phase 3Results postedn = 631NCT02340221
SAPPHIREIndependent statistical analysis of Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 577NCT03906071
SEAMLESSIndependent statistical analysis of A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 482NCT01303796
SERENA-2Independent statistical analysis of A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative…Phase 2Results postedn = 240NCT04214288
SICOG 0109Independent statistical analysis of Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 269NCT01359956
SMA-TBIndependent statistical analysis of Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04575519).Phase 2Results postedn = 426NCT04575519
SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 13,307NCT01994720
SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.Phase 3Results postedn = 450NCT01844986
SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…Phase 3Results postedn = 1,222NCT03521934
SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.Phase 3Results postedn = 5,107NCT01858532
SPIRITIndependent statistical analysis of Antiarrhythmic Effects of Spironolactone in Patients With ICDs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04495712).Phase 4Results postedn = 90NCT04495712
STARTComplete statistical analysis of START, a randomized phase 3 trial of tecemotide (L-BLP25) plus cyclophosphamide versus saline plus placebo in unresectable stage III non-small cell lung cancer, including overall survival, symptom progression,…Phase 3Results postedn = 1,513NCT00409188
STRENGTHIndependent statistical analysis of Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 13,078NCT02104817
STRIDEComplete statistical analysis of the STRIDE phase 3 trial of evidence-based tailored fall prevention versus usual care, including trial design, time-to-event analysis, longitudinal outcomes, safety, and statistical interpretation.Phase 3Results postedn = 5,451NCT02475850
SUN1058Independent statistical analysis of A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 162NCT00265317
SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.Phase 3Results postedn = 3,040NCT00002651
SYGMA2Complete statistical analysis of SYGMA2, a randomized phase 3 trial evaluating as-needed budesonide/formoterol versus twice-daily budesonide with as-needed terbutaline in adults and adolescents with asthma.Phase 3Results postedn = 4,215NCT02224157
TASCIndependent statistical analysis of Aortoiliac Stenosis in Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06020534).Phase NAResults postedn = 655NCT06020534
TASCO1Independent statistical analysis of TASCO1 (NCT02743221), a randomized phase 2 study comparing trifluridine/tipiracil plus bevacizumab with capecitabine plus bevacizumab in previously untreated metastatic colorectal cancer patients non-eligible for intensive therapy.Phase 2Results postedn = 154NCT02743221
TERIKIDSIndependent statistical analysis of Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 166NCT02201108
THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 11,016NCT03354429
THORIndependent statistical analysis of A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations: primary endpoint…Phase 3Results postedn = 629NCT03390504
TIVO-1Independent statistical analysis of A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 517NCT01030783
TNBCIndependent statistical analysis of Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 50NCT02435680
TOPAZ-1Independent statistical analysis of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 810NCT03875235
TRAILIndependent statistical analysis of Letrozole for Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353209).Phase 2Results postedn = 17NCT01353209
TRANSFORM-HFComplete statistical analysis of TRANSFORM-HF, the randomized phase 3 comparison of torsemide versus furosemide for management of heart failure, including time-to-event, rehospitalization, quality-of-life, and depression analyses.Phase 3Results postedn = 2,973NCT03296813
TRITON3Independent statistical analysis of A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 405NCT02975934
TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.Phase 3Results postedn = 732NCT05104866
VERONICAIndependent statistical analysis of the VERONICA phase 2 trial comparing venetoclax plus fulvestrant with fulvestrant in women with ER-positive, HER2-negative locally advanced or metastatic breast cancer after CDK4/6 inhibitor therapy.Phase 2Results postedn = 103NCT03584009
VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…Phase 3Results postedn = 8,246NCT01986881
VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…Phase 3Results postedn = 5,050NCT02861534
VOICEIndependent statistical analysis of the VOICE phase 2 trial of tenofovir 1% gel, oral tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate for prevention of HIV infection in women.Phase 2Results postedn = 5,029NCT00705679
WARCEFComplete statistical analysis of the WARCEF trial, comparing warfarin with aspirin in patients with reduced cardiac ejection fraction, including trial design, time-to-event endpoints, Cox and Poisson regression, reported results, safety, and statistical…Phase 3Results postedn = 2,305NCT00041938
YES-PIndependent statistical analysis of Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 36NCT01887717
ZENITHIndependent statistical analysis of A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 173NCT04896008